Login to Your Account

Aspyrian draws $40M series B from Japanese Internet mogul

By Michael Fitzhugh
Staff Writer

Thursday, March 10, 2016

Aspyrian Therapeutics Inc. said a new $40 million series B financing will help the company complete phase I/II trials of RM-1929, its experimental ADC for recurrent head and neck cancer and potentially for other cancers that have failed standard treatment. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription